3

PRIMARY DOCUMENT

Company: LIGAND PHARMACEUTICALS INC
Filed: June 29, 2022
Period of Report: June 29, 2022
Accession Number: 0000886163-22-000101

View Document ↗ View on SEC.gov ↗